Montor, Wagner Ricardo <br/><br/>
Receptor tyrosine kinases and downstream pathways as druggable targets for cancer treatment: the current arsenal of inhibitors.  [electronic resource] 

 -  Molecular cancer  02 2018 
 - 55 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't; Review 
<br/><br/><label>ISSN: </label>1476-4598 
<br/><br/><label>Standard No.: </label>10.1186/s12943-018-0792-2  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Animals<br/>Antineoplastic Combined Chemotherapy Protocols--adverse effects<br/>Biomarkers, Tumor<br/>Clinical Trials as Topic<br/>Drug Discovery<br/>Drug Resistance, Neoplasm<br/>Humans<br/>Molecular Targeted Therapy<br/>Mutation<br/>Neoplasms--drug therapy<br/>Protein Binding<br/>Protein Kinase Inhibitors--pharmacology<br/>Receptor Protein-Tyrosine Kinases--antagonists & inhibitors<br/>Signal Transduction--drug effects